Moleculin

About Moleculin

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage pharmaceutical company, headquartered in Houston, Texas, developing a portfolio of drug candidates aimed at treating highly resistant tumors and viruses. The company was co-founded by Walter Klemp and Dr. Donald Picker in 2015, with technology licensed from institutions like MD Anderson Cancer Center. Mr. Klemp, the current Chairman and CEO, is a serial entrepreneur with a track record of founding and leading public companies, including Drypers Corporation and Soliton, Inc. His experience involves taking concepts through FDA approval and market launch, and he has been involved with Moleculin, LLC since 2006.

Moleculin's business model is centered on advancing its drug pipeline through rigorous clinical trials to establish safety and efficacy, with the ultimate goal of commercialization. As a clinical-stage entity, its financial structure relies on capital raised from investors, grants, and potential future licensing or partnership agreements, rather than product revenue. The company's strategy involves targeting diseases with significant unmet medical needs, which could lead to accelerated regulatory pathways. A key part of its global strategy includes establishing clinical trial activities in various regions, such as Poland, to leverage local resources and funding.

The company's lead candidate, Annamycin, is a next-generation anthracycline designed to circumvent multidrug resistance and, crucially, to exhibit little to no cardiotoxicity, a common and dose-limiting side effect of traditional anthracyclines. Annamycin is in late-stage clinical development for treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. It has received Fast Track and Orphan Drug Designations from the FDA for both indications.

Moleculin's pipeline also features a portfolio of metabolism/glycosylation inhibitors. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG) engineered to more effectively cross the blood-brain barrier and increase drug half-life, making it a candidate for treating brain tumors like glioblastoma. Another key asset is WP1066, an immune/transcription modulator that inhibits oncogenic transcription factors like p-STAT3 while stimulating a natural immune response. This candidate is being evaluated for brain tumors, pancreatic cancer, and other malignancies, and has received Orphan Drug Designation for brain tumors.